417 results on '"Elisei, W."'
Search Results
2. P544 Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study
3. P1127 Diagnostic delay and economic burden in IBD: a multicenter italian experience in patients treated with biologics
4. P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study
5. N25 Diagnostic delay and economic burden in ibd: a multicenter italian experience in patients treated with biologics
6. T.07.10 PERFORMANCE OF A MULTI-COMPOUNDS NUTRACEUTICAL FORMULATION IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE
7. P373 Real-file prospective experience with adalimumab in inducing remission in ulcerative colitis in Italian primary inflammatory bowel diseases centres
8. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study
9. Predictive value of the “DICA” classification on the outcome of diverticular disease of the colon: an international study: 3.14
10. The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study
11. Predictive value of the ‘DICA’ classification on the outcome of diverticular disease of the colon: 2.14
12. P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study
13. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease
14. Letter: infliximab vs. adalimumab in treating ambulatory perianal fistulising Crohnʼs disease
15. Letter: diverticulosis in inflammatory bowel diseases
16. Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor α in resected acute colonic diverticulitis
17. The prevalence of celiac disease and the appropriateness of the diagnosis in family medicine setting could be lower than expected.
18. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double-blind, randomised, placebo-controlled study
19. Mesalazine and/or lactobacillus casei in maintaining remission of symptomatic uncomplicated diverticular disease of the colon: a randomised, double-blind, placebo-controlled study: 4.26
20. Letter: are infliximab and adalimumab similar for Crohnʼs disease in clinical practice?
21. Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case–control study
22. Musosal tumour necrosis factor α in diverticular disease of the colon is overexpressed with disease severity
23. Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease
24. OC.08.3 THE “DICA” ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS: AN INTERNATIONAL STUDY
25. T04.02.19 CLINICAL AND EPIDEMIOLOGICAL FEATURES OF ULCERATIVE COLITIS PATIENTS IN SARDINIA, ITALY – RESULTS FROM A MULTICENTER STUDY
26. T04.01.15 QUALITY OF LIFE AND PERCEPTION OF CARE FOR ULCERATIVE COLITIS PATIENTS IN SARDINIA: RESULTS OF A MULTICENTER OBSERVATIONAL STUDY
27. OC.08.4 RISK FACTORS FOR ENDOSCOPIC SEVERITY OF DIVERTICULAR DISEASE OF THE COLON AND ITS OUTCOME: A REAL-LIFE CASE-CONTROL STUDY
28. DICA endoscopic classification: 2-year analysis from an international, multicenter prospective study
29. P787 Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicentre study
30. Prognostic value of the Diverticular Inflammation and Complication Assessment (DICA) classification
31. The endoscopic spectrum of segmental colitis associated with diverticulosis
32. International consensus on diverticulosis and diverticular disease. Statements from the 3rd international symposium on diverticular disease
33. Measurement of oxysterols and α-tocopherol in plasma and tissue samples as indices of oxidant stress status
34. OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) AT THE ANO-RECTAL JUNCTION AND ILEOCECAL VALVE
35. P.02.12 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF DIVERTICULAR DISEASE OF THE COLON: A 1-YEAR ANALYSIS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY
36. P.02.29 LONG-TERM EFFICACY OF RIFAXIMIN TO MANAGE THE SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON
37. P.01.31 A COMPARISON OF DIFFERENT TREATMENTS FOR SYMPTOMATIC REFLUX ESOPHAGITIS: A REAL-LIFE STUDY
38. P.05.2 OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) AT THE ANO-RECTAL JUNCTION AND ILEOCECAL VALVE
39. OC.03.3 THE “DICA” ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS
40. Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study
41. Cholesterol molar percent of bile influences the rate of phosphatidylcholine but not cholesterol absorption by the gallbladder mucosa 19.07
42. GS2/010 EVIDENCE FOR MARKED BILIARY LIPID ABSORPTION BY THE GALLBLADDER MUCOSA. A STUDY IN THE ISOLATED IN VITRO PERFUSED HUMAN GALLBLADDER.
43. Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study
44. OC.03.4 IMPACT OF TREATMENTS ON FECAL MICROBIOTA AND FECAL METABOLIC PROFILING IN SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON
45. P.06.14 EFFECTIVENESS AND SAFETY OF PYLERA ® IN PATIENTS INFECTED BY HELICOBACTER PYLORI: A LARGE, PROSPECTIVE, REAL LIFE STUDY
46. OC.03.1 ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) OF SUPERFICIAL COLORECTAL NEOPLASMS AT THE ANAL CANAL AND ILEOCECAL VALVE
47. P.05.7 EPIDEMIOLOGY OF DIVERTICULAR DISEASE OF THE COLON: A PRELIMINARY ANALYSIS FROM THE INTERNATIONAL “DICA” PROSPECTIVE STUDY
48. P.05.9 SURGERY FOR NON-INVASIVE COLORECTAL NEOPLASMS IN A POPULATION-BASED SCREENING PROGRAM
49. OC.12.3: Difficulty Levels of Colorectal Endoscopic Submucosal Dissection (ESD): Preoperative and Intraoperative Prognostic Indicators in the Western Setting
50. P.12.11: Endoscopic Submucosal Dissection (ESD) of Superficial Colorectal Neoplasms at the Anal Canal and Ileocecal Valve
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.